微小RNA在降低HCC分子靶向药物耐药性中的作用

The Role Of MicroRNAs In Reducing The Molecular Targeted Drug Resistance Of HCC

肝细胞癌(HCC)是原发性肝癌的主要组织学类型,大多数患者初诊时即为晚期,生存率较低,一般为5年时间。分子靶向治疗作为晚期HCC患者的重要治疗手段,大部分HCC患者都会因产生不同程度的耐药性而导致肿瘤复发或转移。特异微小RNA通过影响多类信号传导通路参与HCC靶向药耐药的调控,已成为肿瘤及耐药机制研究的热点之一。文章对微小RNA调控HCC耐药性的最新研究进行了综述,以期为解决HCC分子靶向药物耐药性问题找到新的生物标志物和治疗靶点。

Hepatocellular carcinoma(HCC)is the main histological type of primary liver cancer,with most patients initially diagnosed as advanced and having a low survival rate,usually lasting for 5 years.Molecular targeted therapy is an important treatment method for patients with advanced HCC.Most patients with HCC will have tumor recurrence or metastasis due to different degrees of drug resistance.Specific microRNAs participate in the regulation of HCC targeted drug resistance by influencing multiple signaling pathways,and have become a hot topic in the study of tumor and drug resistance mechanisms.This paper provides a review of the latest research on the regulation of HCC resistance by microRNAs,with the aim of finding new biomarkers and therapeutic targets to address the issue of HCC molecular targeted drug resistance.